131I ablation treatment in young females after the Chernobyl accident.
The Chernobyl accident resulted in a number of cases of thyroid cancer in females under the age of 20 y. Many of these individuals were treated with surgical removal of the thyroid gland followed by 131I ablation of residual thyroid tissue. Epidemiologic evidence demonstrates that 131I treatment for thyroid cancer or hyperthyroidism in adult women confers negligible risk of breast cancer. However, comparable data for younger women do not exist. Studies of external radiation exposure indicate that, for radiation exposures of as low as 0.2-0.7 Gy, the risk of breast cancer is greater for infant and adolescent female breast tissues than for adult female breast tissues.


METHODS
The effective half-time of 131I measured in athyrotic patients was used together with the OLINDA/EXM computer code to estimate doses to breast tissue in 10-y-old, 15-y-old, and young adult females from ablation treatment.


RESULTS
The dose to pediatric and young adult female breast tissue associated with a 5.6-GBq (150 mCi) ablation treatment may range from 0.35 to 0.55 Gy, resulting in a lifetime risk of breast cancer ranging from 2-4 cases per 100 such individuals exposed and a lifetime risk of solid tumors ranging from 8 to 17 solid tumors per 100 such individuals exposed. Administration of multiple ablation treatments, as often occurs with metastases, could result in doses ranging from 0.7 to 1 Gy, with corresponding increases in the lifetime cancer risk.


CONCLUSIONS
These estimates suggest the need for additional research and a possible need for surveillance of young Chernobyl thyroid cancer patients who received 131I ablation treatment.
Travis
Curtis C
CC
Science Applications International Corporation, Knoxville, Tennessee, USA. Traviscc@icx.net
Stabin
Michael G
MG
D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000453:epidemiology / Q000209:etiology*; D047852:Chernobyl Nuclear Accident; D002648:Child; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology*; D011210:Power Plants; D018788:Radioactive Hazard Release; D011878:Radiotherapy / Q000009:adverse effects; D013964:Thyroid Neoplasms / Q000532:radiotherapy*; D014455:Ukraine; D014915:Whole-Body Counting
D007457:Iodine Radioisotopes